There are currently 195 clinical trials in Saint Paul, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including United Hospital, Regions Hospital, Regions Hospital Cancer Care Center and Gillette Children's Specialty Healthcare. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
FT576 in Subjects With Multiple Myeloma
NCT05182073
Recruiting
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: University of Minnesota, Saint Paul, Minnesota
Conditions: Multiple Myeloma, Myeloma
Register for Updates
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
NCT05760300
Recruiting
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
03/13/2024
Locations: Nucleus Network, Saint Paul, Minnesota
Conditions: Chronic Hepatitis D Infection
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/11/2024
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Intracerebral Hemorrhage
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: HealthEast Care System, Saint Paul, Minnesota
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT05206513
Recruiting
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in participants aged 6 to 70 years who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
Gender:
All
Ages:
Between 6 years and 70 years
Trial Updated:
03/08/2024
Locations: Neurocrine Clinical Site, Saint Paul, Minnesota
Conditions: Dyskinesia, Cerebral Palsy
Register for Updates
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
NCT04746924
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Metro Minnesota Community Oncology Research Consortium (Mmcorc), Saint Paul, Minnesota
Conditions: Non-small Cell Lung Cancer, NSCLC
Register for Updates
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219
Recruiting
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Site #442, Saint Paul, Minnesota
Conditions: Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Register for Updates
Comparison of ICG Microangiography and Conventional Angiography in Severe Frostbite
NCT05777590
Recruiting
Severe frostbite injury is a significant cause of morbidity in northern climates. Minnesota has some of the highest numbers of severe frostbite injuries in North America. As a result, Regions Hospital has the best opportunity to study this disease process and improve outcomes for frostbite patients. The diagnostic methods for severe frostbite injury vary from institution to institution and there is no standard practice. Commonly utilized methods include conventional angiography, Technetium 99 tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2024
Locations: Regions Hospital, Saint Paul, Minnesota
Conditions: Frostbite
Register for Updates
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
NCT05163314
Recruiting
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.
Gender:
All
Ages:
Between 2 years and 56 years
Trial Updated:
02/20/2024
Locations: Minnesota Epilepsy Group PA, Saint Paul, Minnesota
Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Register for Updates
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
NCT03224767
Recruiting
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/19/2024
Locations: Regions Hospital, Saint Paul, Minnesota +1 locations
Conditions: BRAF V600E Mutation Present, Papillary Craniopharyngioma
Register for Updates
Gait Adaptation and Biofeedback for Cerebral Palsy
NCT05899153
Recruiting
This research aims to evaluate walking function in children with cerebral palsy (CP). The researchers want to understand how children with CP adapt and learn new ways of moving. They have previously found that measuring how a person controls their muscles is important for assessing walking ability and response to interventions. In these studies, they will adjust the treadmill belt speeds and/or provide real-time feedback to evaluate how a child can alter their movement. The feedback will include... Read More
Gender:
All
Ages:
Between 7 years and 18 years
Trial Updated:
02/13/2024
Locations: Gillette Children's, Saint Paul, Minnesota
Conditions: Cerebral Palsy
Register for Updates
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
NCT05695950
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2024
Locations: St. Paul Rheumatology, Saint Paul, Minnesota
Conditions: Dermatomyositis
Register for Updates